These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 10692180)
21. Metaplastic lipid-rich carcinoma of the breast. Varga Z; Robl C; Spycher M; Burger D; Caduff R Pathol Int; 1998 Nov; 48(11):912-6. PubMed ID: 9832063 [TBL] [Abstract][Full Text] [Related]
22. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
23. Sebaceous carcinoma of the eyelids: thirty cases from Japan. Izumi M; Mukai K; Nagai T; Matsubayashi J; Iwaya K; Chiu CS; Goto H Pathol Int; 2008 Aug; 58(8):483-8. PubMed ID: 18705767 [TBL] [Abstract][Full Text] [Related]
24. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Keshgegian AA; Cnaan A Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179 [TBL] [Abstract][Full Text] [Related]
25. Does the volume of ductal carcinoma in situ impact the positive margin rate in patients undergoing breast conservation for invasive breast cancer? Martin-Dunlap TM; Cyr AE; Al Mushawah F; Gao F; Margenthaler JA J Surg Res; 2013 Sep; 184(1):228-33. PubMed ID: 23688789 [TBL] [Abstract][Full Text] [Related]
26. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Paredes J; Lopes N; Milanezi F; Schmitt FC Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107 [TBL] [Abstract][Full Text] [Related]
27. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions. Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376 [TBL] [Abstract][Full Text] [Related]
28. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same? Schorr MC; Pedrini JL; Savaris RF; Zettler CG Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Werling RW; Hwang H; Yaziji H; Gown AM Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930 [TBL] [Abstract][Full Text] [Related]
30. Sebaceous carcinoma of the breast. Murakami A; Kawachi K; Sasaki T; Ishikawa T; Nagashima Y; Nozawa A Pathol Int; 2009 Mar; 59(3):188-92. PubMed ID: 19261098 [TBL] [Abstract][Full Text] [Related]
31. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature? Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177 [TBL] [Abstract][Full Text] [Related]
32. Metaplastic carcinoma of the breast with dominant squamous and sebaceous differentiation in the primary tumor and osteochondroid metaplasia in a distant metastasis: report of a case with review of sebaceous differentiation in breast tumors. Carlucci M; Iacobellis M; Colonna F; Marseglia M; Gambarotti M; Giardina C; Bisceglia M Int J Surg Pathol; 2012 Jun; 20(3):284-96. PubMed ID: 21865268 [TBL] [Abstract][Full Text] [Related]
33. Sebaceous carcinoma of the breast: report of four cases and review of the literature. Švajdler M; Baník P; Poliaková K; Straka L; Hríbiková Z; Kinkor Z; Kazakov DV; Skálová A; Michal M Pol J Pathol; 2015 Jun; 66(2):142-8. PubMed ID: 26247527 [TBL] [Abstract][Full Text] [Related]
34. Basal-like immunophenotype markers and prognosis in early breast cancer. Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B Tumori; 2010; 96(6):966-70. PubMed ID: 21388060 [TBL] [Abstract][Full Text] [Related]
35. Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival. Tot T Ann Surg Oncol; 2015 Aug; 22(8):2532-9. PubMed ID: 25582746 [TBL] [Abstract][Full Text] [Related]
36. Objective quantitative grading. A study of breast ductal hyperplasias and ductal carcinomas in situ. Mariuzzi G; Mombello A; Mariuzzi L; Thompson D; Bartels PH Ann N Y Acad Sci; 1996 Apr; 784():395-402. PubMed ID: 8651587 [No Abstract] [Full Text] [Related]
37. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma. Zekioglu O; Erhan Y; Ciris M; Bayramoglu H; Ozdemir N Histopathology; 2004 Jan; 44(1):18-23. PubMed ID: 14717664 [TBL] [Abstract][Full Text] [Related]
38. Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol; 1997 Nov; 28(11):1221-5. PubMed ID: 9385925 [No Abstract] [Full Text] [Related]
39. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825 [TBL] [Abstract][Full Text] [Related]
40. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients]. Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]